Sasso Magali, Audière Stéphane, Kemgang Astrid, Gaouar Farid, Corpechot Christophe, Chazouillères Olivier, Fournier Céline, Golsztejn Olivier, Prince Stéphane, Menu Yves, Sandrin Laurent, Miette Véronique
R&D Department, Echosens, Paris, France.
R&D Department, Echosens, Paris, France.
Ultrasound Med Biol. 2016 Jan;42(1):92-103. doi: 10.1016/j.ultrasmedbio.2015.08.008. Epub 2015 Sep 19.
To assess liver steatosis, the controlled attenuation parameter (CAP; giving an estimate of ultrasound attenuation ∼3.5 MHz) is available with the M probe of the FibroScan. We report on the adaptation of the CAP for the FibroScan XL probe (center frequency 2.5 MHz) without modifying the range of values (100-400 dB/m). CAP validation was successfully performed on Field II simulations and on tissue-mimicking phantoms. In vivo performance was assessed in a cohort of 59 patients spanning the range of steatosis. In vivo reproducibility was good and similar with both probes. The area under receiver operative characteristic curve was equal to 0.83/0.84 and 0.92/0.91 for the M/XL probes to detect >2% and >16% liver fat, respectively, as assessed by magnetic resonance imaging. Patients can now be assessed simultaneously for steatosis and fibrosis using the FibroScan, regardless of their morphology.
为评估肝脂肪变性，使用FibroScan的M探头可获得受控衰减参数（CAP；给出约3.5MHz超声衰减的估计值）。我们报告了在不改变数值范围（100 - 400dB/m）的情况下，将CAP应用于FibroScan XL探头（中心频率2.5MHz）的情况。CAP在Field II模拟和组织模拟体模上成功进行了验证。在一组涵盖脂肪变性范围的59例患者中评估了其体内性能。两种探头的体内重现性均良好且相似。通过磁共振成像评估，M/XL探头检测>2%和>16%肝脂肪时，受试者操作特征曲线下面积分别为0.83/0.84和0.92/0.91。现在，无论患者形态如何，均可使用FibroScan同时评估其脂肪变性和纤维化情况。
Zotero 插件